

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

**UNAUDITED FINANCIAL RESULTS OF
CR JIANGZHONG
FOR THE SIX MONTHS ENDED 30 JUNE 2026**

On 21 August 2026, CR Jiangzhong released its interim report for the six months ended 30 June 2026.

China Resources Jiangzhong Pharmaceutical Co., Ltd. (華潤江中藥業股份有限公司) (“**CR Jiangzhong**”) is a company incorporated in the People’s Republic of China. The shares of CR Jiangzhong are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Jiangzhong is owned as to approximately 43.10% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 26.10% of CR Jiangzhong, which is accounted for as a subsidiary of the Company.

On 21 August 2026, CR Jiangzhong released its interim report for the six months ended 30 June 2026 (the “**CR Jiangzhong Unaudited Financials**”). Set out below is the key financial information of the CR Jiangzhong Unaudited Financials:

	As of 30 June 2026 (RMB) (unaudited)	As of 31 December 2025 (RMB) (audited)	Decrease (%)
Total assets	6,737,699,075.38	6,880,863,149.41	–2.08%
Net assets attributable to shareholders of the listed company	3,958,896,805.55	4,022,814,419.53	–1.59%
	For the six months ended 30 June 2026 (RMB) (unaudited)	2025 (RMB) (unaudited)	Increase/ Decrease (%)
Revenue	1,932,287,474.23	2,141,118,142.51	–9.75%
Net profit attributable to the shareholders of the listed company	491,400,125.12	522,337,503.28	–5.92%
Net profit attributable to the shareholders of the listed company (after extraordinary gains or losses)	469,605,523.74	482,103,086.76	–2.59%
Net cash flow from operating activities	696,129,289.46	651,787,675.27	6.80%
Basic earnings per share (RMB/share)	0.78	0.82	–4.88%
Diluted earnings per share (RMB/share)	0.78	0.82	–4.88%
Weighted average return on net asset	11.51%	12.89%	decreased by 1.38 percentage points

As determined by the board of directors of CR Jiangzhong, CR Jiangzhong proposed to distribute a cash dividend of RMB5 (inclusive of tax) for every 10 shares to all CR Jiangzhong’s shareholders based on the total share capital of CR Jiangzhong on the date of equity distribution registration. Such proposal has been submitted for shareholders’ approval at CR Jiangzhong’s 2025 annual general meeting.

The CR Jiangzhong Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to CR Jiangzhong only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Jiangzhong Unaudited Financials, please refer to the interim report for the six months ended 30 June 2026 published by CR Jiangzhong on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 21 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.